孟鲁司特治疗过敏性紫癜患儿的疗效观察

Observation on curative effect of Montelukast in treating Henoch-Schonlein purpura in children

目的研究白三烯受体拮抗剂孟鲁斯特治疗小儿过敏性紫癜的临床疗效。方法将120例过敏性紫癜患儿随机分成两组，对照组采用常规方法治疗，治疗组在常规治疗的基础上加用孟鲁斯特（2～6岁为4mg／d，6～13岁为5mg／d，睡前口服）治疗，两组进行疗效比较。结果对照组显效40例，有效5例，无效15例；治疗组显效50例，有效9例，无效1例，治疗组加用孟鲁司特后疗效更优（P〈0．05）。结论白三烯受体参与过敏性紫癜的发病过程，用白三烯受体拮抗剂孟鲁斯特治疗过敏性紫癜疗效确切，无明显不良反应。

Objective To investigate the clinical effects of Montelukast in treating Henoch-Schonlein purpura children. Methods 120 children with Henoch-Schonlein purpura were randomly divided into two groups. The control group was treated with conventional medication. The treatment group was treated with montelukast sodium （2 - 6 year-old given 4 mg/d,6 - 13 year-old given 5 rag/d, per os before sleep ） in addition. The clinical effects of the two groups were compared. Results The cure rate of treatment group was obviously higher than that of the conventional group （P 〈 0.05）. The clinical effect in the control group： excellent 40 cases, utility 5 cases, ineffective 15 cases; the clinical effect in the treatment group： excellent 50 cases, utility 9 cases, ineffective 1 case. Conclusion There is a close relationship between leukotriene receptor expression in Henoch-Schonlein purpura, leukotriene receptor antagonist is effective in treatment of Henoch-Schonlein purpura, with no obvious adverse reaction.